Cisplatin-associated thrombosis

Anti-Cancer Drugs

Volumn 19, Issue 9, 2008, Pages 927-929

  Jafri, Mariam ^a   Protheroe, Andrew ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cisplatin; Pathophysiology; Thrombosis

Indexed keywords

BLEOMYCIN; CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; WARFARIN;

ADULT; ARTERY THROMBOSIS; ARTICLE; BRAIN INFARCTION; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DELIRIUM; DOPPLER ECHOGRAPHY; FEVER; FOOT PAIN; HEPARINIZATION; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; RASH; RETROPERITONEAL CANCER; SEPSIS; SURGICAL THROMBECTOMY; THORAX PAIN;

ADULT; CAROTID ARTERY THROMBOSIS; CISPLATIN; CORONARY THROMBOSIS; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; THROMBOSIS;

EID: 52649099592     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283100e9c     Document Type: Article

References (15)

1. Barcelo R, Lopez-Vivanco G, Mane JM, Rubio I, Munoz A, Fernandez R. Distal tschaemic changes related to combination chemotherapy with gemcitabtne and ctsplatin: description of four cases. Ann Oncol 2000; 11:1191-1194.
2. Barcelo R, Munoz A, Lopez-Vivanco G. Prospective evaluation of major vascular events in patients with non-small cell lung cancer treated with cisplatin and gemcitabine. Cancer 2005; 104:1110-1111.
3. Jacobson GM, Kamath RS, Smith BJ, Goodheart MJ. Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynaecol Oncol 2005; 96:470-474.
4. Weijl Nl, Rutten MFL, Zwinderman AH, Jan Keizer J, Nooy MA, Rosendaal FR, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Onc 2000; 18: 2169-2178.
5. Piketty AC, Rechon A, Laplanche A, Nouyrigat E, Droz JP, Theodore C, Fizazi K. The risk of thromboembolic events is increased in patients with germ cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer 2005; 93:909-914.
6. Meinardi MT, van der Graff WTA, van Veldhuisen DJ, Runne WJ, Sluiter WJ, de Vries EGE, et al. Cardiovascular morbidity in long term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18:1725-1732.
7. Hansen SW, Olsen N, Rossing N, Rerth M. Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin. Ann Oncol 1990; 1:289-292.
8. Van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodrigus PT, et al. Long term risk of cardiovascular disease in 5 year survivors of testicular cancer. J Clin Oncol 2006; 24:467-475.
9. Anders JC, Grigsby PW, Singh AK. Cisplatin chemotherapy (without erythropoietin) and risk of life threatening thromboembolic events in carcinoma of the uterine cervix: the tip of the iceberg? Rev Lit Radial Oncol 2006; 1:14.
10. Matthews J, Goel R, Evans WK, Shamji F, Stewart DJ. Arterial occlusion in patients with peripheral vascular disease treated with platinum-based regimens for lung cancer. Cancer Chemother Pharmacol 1997; 40: 19-22.
11. Zecchina G, Ghio P, Bosio S, Cravino M, Camaschella C, Scagliotti GV. Reactive thrombocytosis might contribute to chemotherapy-related thrombophilia in patients with lung cancer. Clin Lung Cancer 2007; 8: 264-267.
12. Ohashi S, Yazumi S, Nishio A, Fukui T, Asada M, Chiba T. Acute cerebral infarction during combination chemotherapy with S1 and cisplatin for a young patient with a mucin producing adenocarcinoma of the stomach. Intern Med 2006; 45:1049-1053.
13. Gerl A. Vascular toxicity associated with chemotherapy for testicular cancer. Anticancer Drugs 1994; 5:607-614.
14. Dursun B, He Z, Somerset H, Oh D-J, Faubel S, Edelstein CL. Caspases and calpain are independent mediators of cisplatin-induced endothelial cell necrosis. Am J Physiol Renal Physiol 2006; 291 :1578-1587.
15. Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res 2000; 99:503-509.